The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Seagen; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Hiroki Hara
Honoraria - Asahi Kasei; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD; Ono Pharmaceutical
Research Funding - ALX Oncology (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Janssen Oncology (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Akinori Miura
Honoraria - Bristol-Myers Squibb Company; MSD; ONO PHARMACEUTICAL
Travel, Accommodations, Expenses - Bristol-Myers Squibb Company
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiihi-Sankyo; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); IQVIA (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)
 
Keigo Komine
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Incyte Japan; Kyowa Kirin International; Nihonkayaku
Research Funding - Janssen (Inst)
 
Chikara Kunisaki
No Relationships to Disclose
 
Hiroshi Yabusaki
No Relationships to Disclose
 
Akiko Hagiwara
Employment - Janssen; Sanofi; Takeda
Stock and Other Ownership Interests - Janssen; Sanofi
 
Noriko Suzuki
Employment - Janssen
 
Kiichiro Toyoizumi
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Joshua C Curtin
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
Patents, Royalties, Other Intellectual Property - Janssen Research & Development (Inst)
 
Sanjib Chowdhury
Employment - Janssen Research & Development
 
Roland Elmar Knoblauch
Employment - Janssen Oncology
Stock and Other Ownership Interests - Johnson & Johnson
Patents, Royalties, Other Intellectual Property - Johnson and Johnson (Inst)
Travel, Accommodations, Expenses - Johnson & Johnson
 
Toshihiko Doi
Honoraria - Daiichi Sankyo
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Gilead Sciences; Kaken Pharmaceutical; Kyowa Hakko Kirin; NanoCarrier; Noil-Immune Biotech; Noil-Immune Biotech; Oncolys BioPharma; Otsuka; PRA Health Sciences; Rakuten Medical; SHIONOGI; Sumitomo Pharma; Takeda
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Janssen (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); PRA Health Sciences (Inst); RIN Institute (Inst); SHIONOGI (Inst); Taiho Pharmaceutical (Inst)